Abstract

Venkatesan R.*, T. Srinivasa Rao, Chandanam Sreedhar, Harsha K. Tripathy, Manju S. V. and Kavana B B

ABSTRACT

Metformin, recognized as the primary first-line oral agent for managing type 2 diabetes, acts as a potent blood glucose-lowering agent. Operating as a biguanide drug, it exhibits efficacy by mitigating hepatic glucose production, impeding intestinal glucose absorption, and enhancing insulin sensitivity, resulting in a notable reduction in both basal and postprandial blood glucose levels. Concurrently, Evogliptin, a Dipeptidyl peptidase-4 (DPP-4) inhibitor, emerges as a novel oral antihyperglycemic agent, influencing insulin secretion and satiety through the reduction of endogenous glucagon-like peptide 1 (GLP-1) degradation. This review emphasizes recent advancements in analytical techniques for estimating Metformin Hydrochloride and Evogliptin Tartrate, considering both their combined and individual applications of evogliptin and Metformin Hydrochloride. Various methods, including UV spectroscopy, HPLC, Stability-Indicating RP-HPLC, and HPTLC, have been reported for both combined and individual estimations.